Reports Q1 revenue $220.4M, consensus $182.62M. "We are pleased to report strong revenue growth in Q1, with double-digit year-over-year revenue increases for all six of our marketed and partnered products," said CEO Matthew Klein. "In addition, we remain on track to share readouts from four clinical studies, including three registration-directed studies, in the second quarter."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PTCT:
- PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
- William Blair healthcare analysts to hold an analyst/industry conference call
- PTC Therapeutics participates in a conference call with JPMorgan
- Is PTCT a Buy, Before Earnings?
- PTC Therapeutics price target raised to $65 from $60 at Truist
